Neuropsychiatric Disease and Treatment (May 2023)

The Efficacy and Cognitive Impact of Perampanel Monotherapy in Patients with Self-Limited Epilepsy with Centrotemporal Spikes: A Retrospective Analysis

  • Yue X,
  • Liu XM,
  • Chen J,
  • Chen HY,
  • Tan QQ,
  • Zhou Y

Journal volume & issue
Vol. Volume 19
pp. 1263 – 1271

Abstract

Read online

Xuan Yue,1,* Xiao-Ming Liu,1,* Jiao Chen,1,* Hai-Yun Chen,2 Qian-Qian Tan,2 Yong Zhou2 1Department of Neurology, XuZhou Children’s Hospital, XuZhou, People’s Republic of China; 2Puluo (Wuhan) Medical Biotechnology Co., LTD, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiao-Ming Liu, Department of Neurology, XuZhou Children’s Hospital, Sudi North Road, No. 18, XuZhou, JiangSu, People’s Republic of China, Tel +18952173923, Email [email protected]: The third generation of antiepileptic medication (ASM) perampanel (PER), is mostly used as an add-on treatment for refractory epilepsy patients, and rarely used as a monotherapy. This study aims to observe the efficacy and assess the cognitive effects of PER monotherapy in patients with self-limited epilepsy with centrotemporal spikes (SeLECTS).Patients and Methods: Through screening, 86 patients who were first diagnosed with SeLECTS and treated with PER monotherapy were included in this study. All patients were followed up at least 12 months, and Evaluated the efficacy and safety of PER by observing the seizures of patients. At the same time, we used the P300 event-related potential (ERP) component and Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) to evaluate the cognitive changes in children before and after treatment with PER.Results: Ten percent of the children experienced adverse effects, such as dizziness, gait instability, and irritability. The drug retention rate at the last follow-up was 98.83%. Further more, the P300 ERP component and WISC-IV tests were performed no significant difference before and 12 months after PER monotherapy in SeLECTS children.Conclusion: The third-generation of ASM PER monotherapy had a clear effect in children with SeLECTS. A small dose of PER can control seizures well and has no obvious effect on cognitive development.Keywords: self-limited epilepsy with centrotemporal spikes, P300 ERP component, Wechsler Intelligence Scale for Children-Fourth Edition, perampanel, monotherapy

Keywords